Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

 Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil

Shots:

  • The P-II POC study assess safety and efficacy of ANG-3777 (2.0 mg/kg, IV) + SOC vs PBO + SOC in ~100 patients in a ratio (1:1) hospitalized with confirmed COVID-19 pneumonia with 1EPs as the proportion of patients alive, without the need for mechanical ventilation and renal replacement therapy (on an ongoing basis) @28day
  • Following the success of the P-II study, the company plans to submit an IND for the therapy in the US. Additionally, Angion is conducting a P-III study of ANG-3777 to improve kidney function and reduce the severity of transplant-associated AKI in patients showing evidence of early kidney dysfunction and in a P-II clinical trial for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass
  • ANG-3777 is designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair

Click here to read full press release/ article | Ref: PRNewswire | Image: Angion

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post